ClinicalTrials.Veeva

Menu

Research on Speech Development Trajectories and Predictive Models in Children With Autism Spectrum Disorder

C

Chongqing Medical University

Status

Not yet enrolling

Conditions

Autism Spectrum Disorder (ASD)
Speech

Treatments

Behavioral: Approaches to ASD social intervention

Study type

Observational

Funder types

Other

Identifiers

NCT07472829
SDTPMASD

Details and patient eligibility

About

Recent studies indicate that children with ASD have a significantly higher risk of co-occurring speech sound disorders than typically developing children. Early atypical speech development may be a critical yet overlooked bottleneck hindering their language improvement. Given the unique phonetic features of Mandarin, it is essential to investigate speech development in Mandarin-speaking children with ASD. This study aims to construct developmental trajectories and establish early identification and prognosis prediction models for this population.

Full description

  1. Procedures. This study plans to enroll 60 children with autism spectrum disorder (ASD group) and 60 typically developing children (TD group), aged 18-60 months, matched by age and sex. At baseline, both groups will undergo assessments of development, language, and parent-child interaction, as well as fNIRS; the ASD group will additionally receive clinical diagnostic evaluations. Subsequently, a one-year follow-up will be conducted, with both groups completing language and parent-child interaction assessments at 3, 6, 9, and 12 months, and undergoing repeated developmental and fNIRS evaluations at the final 12-month visit.
  2. Demographic questionnaire and clinical data. The demographic questionnaire is completed by the child's primary caregiver, detailing child's name, gender, date of birth, height, weight, heart rate. Clinical data will be ascertained from the medical records, including information about DSM-5 diagnosis and comorbid conditions.
  3. Sample size. This study ultimately determined a sample size of 120 participants (60 in the ASD group and 60 in the TD group). The estimation was based on the minimum sample size required to analyze the "group × time" interaction effect using a mixed-effects model (88 participants, achieving 85% power), and fully considered the following factors: ① Meeting the analytical requirements for both the main effects of group and time; ② The need to increase the sample size to 110 participants if multiple comparison corrections (Bonferroni correction, α=0.0083) are applied to the six speech indicators; ③ Considering practical operational challenges such as the long follow-up period, multiple repeated measurements, and anticipated dropout rates, the sample was ultimately expanded to 120 participants to ensure the robustness of the study.
  4. Statistical analysis. SPSS 25.0 software (SPSS Inc) was used for statistical analysis for the scale data, The speech development trajectories of the two groups can be analyzed using longitudinal methods such as mixed-effects models. Repeated measures ANOVA will compare speech characteristics between the ASD and TD groups at five time points (baseline, 3, 6, 9, and 12 months). Correlation analysis (Pearson or Spearman, depending on normality) will assess the relationship between speech development and core ASD symptoms. ANOVA/MANOVA will examine group differences in speech perception tasks, and exploratory factor analysis will identify underlying factors influencing speech perception.All statistical analyses were conducted with a statistical threshold P-value of <0.05. The data collected through fNIRS will be performed via NirSpark analysis software.
  5. Ethical matters and data protection. The children participated in the study will sign the informed consent (obtained from the guardian). And this study was approved by the local ethics committee. children's name will be abbreviated and the research data will be assigned a code then to provide to the researcher. The authorization from parents on the children's health information remains valid until the study is completed. After that, researchers will delete private information from the study record.

Enrollment

120 estimated patients

Sex

All

Ages

18 to 60 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Diagnosed as typically developing children by two or more associate chief physicians.
  • Gender- and age-matched to the ASD group.
  • Participants whose native language is Chinese.

Exclusion criteria

  • Participants not meeting the age requirement.
  • Presence of orofacial motor and swallowing dysfunction.
  • Hearing impairment.
  • Participants whose native language isn't Chinese.
  • Neurological disorders (such as encephalitis or seizures) and comorbid psychiatric disorders.

Trial design

120 participants in 2 patient groups

ASD group
Description:
Inclusion criteria: Diagnosed by two or more associate chief physicians using the DSM-5 diagnostic criteria. Participants aged between 18 and 60 months. Participants with a vocabulary size ranging from 0 to 50 words, as assessed using the Chinese Communicative Development Inventory. Participants whose native language is Chinese. Exclusion criteria: Participants not meeting the age requirement. Presence of orofacial motor and swallowing dysfunction. Hearing impairment. Participants whose native language isn't Chinese. Neurological disorders (such as encephalitis or seizures) and comorbid psychiatric disorders.
Treatment:
Behavioral: Approaches to ASD social intervention
TD group
Description:
Inclusion Criteria: Diagnosed as typically developing children by two or more associate chief physicians. Gender- and age-matched to the ASD group. Participants whose native language is Chinese. Exclusion Criteria: Participants not meeting the age requirement. Presence of orofacial motor and swallowing dysfunction. Hearing impairment. Participants whose native language isn't Chinese. Neurological disorders (such as encephalitis or seizures) and comorbid psychiatric disorders.

Trial contacts and locations

0

Loading...

Central trial contact

Li Chen, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems